CI-1 KALYDECO® (Ivacaftor) Treatment for Cystic Fibrosis Vertex Pharmaceuticals Incorporated Pulmonary and Allergy Drugs - Vertex Pharmaceuticals - Document - PDFSEARCH.IO - Document Search Engine

Back to Results

First Page	Meta Content
	CI-1 KALYDECO® (Ivacaftor) Treatment for Cystic Fibrosis Vertex Pharmaceuticals Incorporated Pulmonary and Allergy Drugs Add to Reading List Open Document File Size: 1,30 MB Share Result on Facebook Company CF / Clinical Development Vertex Pharmaceuticals Incorporated / Global Regulatory Affairs Vertex Pharmaceuticals Incorporated / Cystic Fibrosis Vertex Pharmaceuticals Incorporated / / Event FDA Phase / Product Issues / Force Majeure / / Facility Translational Science University / Translational Science University of Pittsburgh Ivacaftor Overview / / IndustryTerm Treatment for Cystic Fibrosis / treatment of cystic fibrosis / / MedicalCondition inflammation Progressive lung disease Pancreatic insufficiency / only single-organ dysfunction / Pancreatic Insufficiency Malnutrition CFTR / focal biliary cirrhosis Frequent lung infections / Digestive problems Reduced fertility Infertility / Multi-system Disease Sinus infection / cystic fibrosis transmembrane conductance regulator / Nasal polyps Bile duct obstruction / cystic fibrosis / MS / / Organization University of Pittsburgh / Stanford University / Cystic Fibrosis Foundation / Translational Science University / Allergy Drugs Advisory Committee / Advisory Committee / Translational Science University of Pittsburgh Ivacaftor Overview / / Person Joseph M. Pilewski / Jeffrey Chodakewitz / Antoinette Paone / Safety Mark Higgins / / Position Chief Medical Officer / Professor / Vice President / Senior Clinical Director / Associate Professor / Professor of Medicine / / Product thrive / Eight Additional Gating / G551D / ion transport Fluid / R117H / electrolyte imbalance Defective ion transport Lung Disease Infertility / / ProvinceOrState South Dakota / / RadioStation CFTR / / SocialTag Pancreas disorders Anilides Ivacaftor Phenols Quinolones Cystic fibrosis transmembrane conductance regulator Cystic fibrosis Congenital absence of the vas deferens Vertex Pharmaceuticals Biology